Blogs home Featured Image

It’s mostly preaching to the converted to say that ‘open-source is changing enterprises’. The 2020 Open Source Security and Risk Analysis (OSSRA) Report found that 99 per cent of enterprise codebases audited in 2019 contained open-source components, and that 70 per cent of all audited codebases were entirely open-source.

Hearts and minds have most certainly been won, then, but there are still a surprising number of enterprise outliers when it comes to adopting open-source tools and methods. It’s no surprise that regulated industries are one such open-source averse group.

It’s still difficult to shake off the reputation open-source resources can have for being badly-built, experimental, or put together by communities with less recognisable credentials than big players in software. When your industry exists on trust in your methods – be it protecting client finances in banking, or the health of your patients in pharma – it’s often easier just to make do, and plan something more adventurous ‘tomorrow’.

This approach made a certain amount of sense in years past, when embracing open-source was more a question of saving capex with ‘free’ software, and taking the risk.

Then, along comes something like Covid-19, and the CEO of Pfizer – who are now among those leading the way in a usable vaccine – singing the praises of open-source approaches back in March 2020. Months down the line, AstraZeneca and Oxford University’s 70 percent-efficacy Covid-19 vaccine emerged. AstraZeneca is having a public conversation around how it’s “embracing data science and AI across [the] organisation” while it continues to “push the boundaries of science to deliver life-changing medicines”.

Maybe tomorrow has finally arrived.

At Mango, our primary interest is in data science and analytics, but we also have a great interest in the open-source programming language R when we’re thinking about statistical programming. We’re not attached to R for any other reason than we find it hugely effective in overcoming the obstacles the pharmaceutical industry recognises implicitly – accessing better capabilities, and faster.

With a growing number of pharmaceutical companies starting to move towards R for clinical submissions, we thought it would be useful to find out why. Asking experts from Janssen, Roche, Bayer and more, we collected first-hand use cases, experiences and stories of challenges overcome, as well as finding out how these companies are breaking the deadlock of open-source’s reputation versus its huge potential for good in a world where everything needs to move faster, while performing exceptionally. Watch the full round table recording here.

If you’d like to find out more, please get in touch and we’d be happy to continue the conversation.

Author: Rich Pugh, Chief Data Scientist at Mango

rstudioconf
Blogs home Featured Image

We’re delighted to be sponsoring the rstudio::global conference this year. It’s a credit to the community that such events (including our own flagship EARL conference) have been so readily able to respond to the pandemic lockdown and transform to a fully virtual presence, providing inspirational talks on all things R. 

We are excited to see John Burn-Murdoch, senior data visualisation journalist at the Financial Times amongst the keynotes.  John led the FT’s data-driven coverage of the pandemic, amassing an enormous following on social media for his incisive reporting.  It will be fascinating to hear the lessons he has learned from his reporting and visualisations and how he addressed the challenges of communicating often complex findings to the population at large. It was our pleasure to have had John speak at the EARL conference in both 2014 and 2016 – so we know that the rstudio::global audience can expect a riveting presentation. 

With a packed itinerary and 24-hour streaming for accessibility all over the world, there will be some extremely useful presentations and stimulating conversations to be had for the 10,000 expected data professionals.  

As a sponsor of this event and as RStudio’s longest serving Full Service Certified Partner, we would like this opportunity to invite attendees to meet us in our virtual booth. Whether you are scaling the use of R in your organisation and require technical advice on setup or configuration, lacking internal IT to support the required maintenance of RStudio products or have reservations around the validation of open-source packages from a security or malware perspective, we can help.   

Some of the services that we offer include: 

  • A Managed Service providing a scalable RStudio environment which can be effectively built up, run in the cloud and fully maintained by Mango, to minimise the responsibility and burden on your inhouse IT teams. 
  • An On-Premise solution designed to address current in-house service gaps; following an Installation, Accelerate and Healthcheck review, this service offers the full installation, configuration and maintenance of RStudio products. 
  • A new validation service through ValidR® presents a validated collection of the 150 most popular industry leading R packages, such as those within the tidyverse and can be deployed with RStudio Package Manager (RSPM) to mitigate any uncertainty of using opensource software, with guaranteed reproducibility for any data science team. 

We’re very much looking forward to seeing you at the event on 21st January – don’t forget to sign up for this event now if you haven’t already. 

#Rstudioconf2021 #rstats #RStudiofullservicepartner